<div xmlns="http://www.w3.org/1999/xhtml">
<p>Tetrabenazine is not the only drug registered by the FDA for the treatment of Chorea in Huntington’s disease. On the 3rd April 2017 Deutetrabenazine (trade name Austedo) was approved by the U.S. Food &amp; Drug Administration (FDA) for the treatment of chorea associated with Huntington’s Disease (<a ref-type="bibr" href="#j_ajon-2022-006_ref_2">U.S. Department of Health and Human Services, 2017</a>). On the 2nd June 2021 Deutetrabena zine (product name Austedo) was entered on in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer Oxf Engl o the Australian Registry of Therapeutic Goods for the treatment of chorea associated with Huntington’s Disease (<a ref-type="bibr" href="#j_ajon-2022-006_ref_1">Australian Government, 2021</a>).</p>
</div>

Huntington’s Disease: A Nursing Perspective

Australasian Journal of Neuroscience

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Huntington’s Disease: A Nursing Perspective

Data publikacji: 11 lip 2022

Zakres stron: 12 - 12

DOI: https://doi.org/10.21307/ajon-2022-006

© 2022 Sarah V Samperi et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.